Oncology

Epalrestat could prevent metastasis in patients with basal-like triple-negative breast cancer.

High consumption of isoflavones reduced all-cause mortality in patients with breast cancer by 21%.

Repurposed drugs may provide new therapies for cancer.

Isoflavone supplements may influence outcomes among patients with breast cancer.

Most models were cancer-free within 6 weeks of treatment with selenomab-drug conjugates.

Next-generation antibody treatments effectively deliver cytotoxic drugs to tumors.

Corticosteroids, chemotherapy, and immunotherapy may all be used to treat castration-resistant prostate cancer.

Top news of the week in oncology and cancer drug development.

Checkpoint inhibitors plus myeloid-derived suppressor cell inhibitors show promise as prostate cancer treatment.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival in patients with breast cancer.

The addition of abemaciclib to fulvestrant appeared to effectively improve progression-free survival.

New research indicates that high consumption of certain dairy products may either increase or decrease the risk of developing breast cancer, depending on the food.

High yogurt intake may protect against breast cancer, while processed cheeses may increase cancer risk.

Mapping lung cancer cell interactions can unveil new targeted treatment techniques.

Vitamin C observed to kill cancer stem-like cells.

Nanomachines produce a florescent response when in contact with cancer biomarkers.

Muscle composition may be predictive of chemotherapy toxicity.

Clinical practice guideline on human papillomavirus (HPV) vaccination can improve prevention of cervical cancer.

Eli Lilly and Company recently announced positive late-stage results in its clinical trial testing a combination of its experimental breast cancer drug and another widely-used treatment.

Cancer-focused continuing education programs seek to enhance cancer care at specialty pharmacies.

The risk of a second cancer remained high even 30 years after treatment.

Progression-free survival with IMMU-132 increases from an average of 3.5 months to 16.6 months in patients with breast cancer.

Top news of the day from across the health care landscape.

Top news of the week in oncology and cancer drug development.

Top news of the day from across the health care landscape.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

Senescent cells communication via integrin beta 3 expression.